Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Continuing enasidenib treatment for patients with mutant- IDH2 (m IDH2) relapsed or refractory acute myeloid leukemia (R/R AML) with stable disease may result in improved survival and responses over time
    Meeting Abstract

    Stein, E. M.; Stone, R. M.; Pollyea, D. A.; Roboz, G. J.; Altman, J. K.; DiNardo, C. D.; de Botton, S.; Tu, N.; Swern, A. S.; Tosolini, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in the United States
    Meeting Abstract

    Stein, E. M.; Xie, J.; Duchesneau, E.; Bhattacharyya, S.; Ndife, B.; Bonifacio, G.; Joseph, G. J.
    Blood (2017)

    Fulltext@MSK | Save
  • Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia
    Meeting Abstract

    Quek, L.; David, M.; Kennedy, A.; Metzner, M.; Amatangelo, M.; Shih, A. H.; Stoilova, B.; Karamitros, D.; Quivoron, C.; Heiblig, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Enasidenib monotherapy is effective and well-tolerated in patients with previously untreated mutant-IDH2 (m IDH2) acute myeloid leukemia (AML)
    Meeting Abstract

    Pollyea, D. A.; Tallman, M. S.; De Botton, S.; DiNardo, C. D.; Kantarjian, H. M.; Collins, R. H.; Stein, A. S.; Xu, Q.; Tosolini, A.; Gupta, I.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Early results from a biomarker-directed phase 2 trial of SY-1425 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) demonstrate DHRS3 induction and myeloid differentiation following Sy-1425 treatment
    Meeting Abstract

    Jurcic, J. G.; Raza, A.; Vlad, G.; Stein, E. M.; Roshal, M.; Bixby, D. L.; Boyer, D. F.; Vigil, C. E.; Syrbu, S.; Sekeres, M. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies
    Meeting Abstract

    Goldberg, A. D.; Horvat, T. Z.; Hsu, M.; Devlin, S. M.; Cuello, B. M.; Daley, R. J.; King, A. C.; Buie, L. W.; Glass, J. L.; Mauro, M. J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Widespread use of measurable residual disease in acute myeloid leukemia practice
    Meeting Abstract

    Epstein-Peterson, Z. D.; Devlin, S. M.; Stein, E. M.; Estey, E. H.; Tallman, M. S.
    Blood (2017)

    Fulltext@MSK | Save
  • Myeloid malignancies following luminal gastrointestinal cancer: High incidence of deletion 5q and DNTM3A mutations
    Meeting Abstract

    Epstein-Peterson, Z. D.; Devlin, S. M.; Stein, E. M.; Klimek, V. M.; Saltz, L. B.; Tallman, M. S.
    Blood (2017)

    Fulltext@MSK | Save
  • A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: Results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML)
    Meeting Abstract

    Dawson, M.; Stein, E. M.; Huntly, B. J. P.; Karadimitris, A.; Kamdar, M.; de Larrea, C. F.; Dickinson, M. J.; Yeh, P. S. H.; Daver, N.; Chaidos, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: Initial results from a phase 1 trial
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Mims, A. S.; Savona, M. R.; Pratz, K.; Stein, A. S.; Fathi, A. T.; Stone, R. M.; Pollyea, D. A.; Odenike, O.; more...
    Blood (2017)

    Fulltext@MSK | Save